Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02928445 · ClinicalTrials.gov registry record · Phase 2
Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension
A Phase 2 study, sponsored by Axovant Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
NCT02928445 is a Phase 2 study that was terminated before completion, run by Axovant Sciences. The registered enrollment target is 240 participants.
The verdict
NCT02928445, a Phase 2 study, was terminated before completion, sponsored by Axovant Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
Study Summary
This 6-month extension study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) in subjects with Dementia with Lewy bodies (DLB) who have participated in the double-blind, placebo-controlled, lead-in study RVT-101-2001.
Interventions
- DRUG RVT-101 35 mg
- DRUG RVT-101 70 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02928445
The ClinicalTrials.gov registry entry for NCT02928445 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Axovant Sciences, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RVT-101 35 mg is the first listed.
NCT02928445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02928445 about?
NCT02928445 is a clinical study titled "Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension". This 6-month extension study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) in subjects with Dementia with Lewy bodies (DLB) who have participated in the double-blind, placebo-controlled, lead-in study RVT-101-2001.
What is the current status of trial NCT02928445?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2016-10. Estimated completion is 2018-02.
What interventions are being tested in trial NCT02928445?
The interventions under investigation include: RVT-101 35 mg (DRUG), RVT-101 70 mg (DRUG).
Who is sponsoring clinical trial NCT02928445?
This trial is sponsored by Axovant Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.